- Tytuł:
- Immunogenicity and safety assessment of a SARS-CoV-2 recombinant spike RBD protein vaccine (Abdala) in paediatric ages 3–18 years old: a double-blinded, multicentre, randomised, phase 1/2 clinical trial (ISMAELILLO study)
- Autorzy:
- Źródło:
- In eClinicalMedicine September 2023 63
Czasopismo naukowe